FDA Drug Approval Package, Saxenda (liraglutide), NDA 206321 — Original Approval & Supplements

This FOIAdocs regulatory document collection brings together FDA approval records for Saxenda (liraglutide), NDA 206321, sponsored by Novo Nordisk. The package contains 43 FDA documents totaling 1,999 pages, organized by original application and supplemental submission.

Instead of locating and downloading individual records across the application history, buyers receive a research-ready collection with the FDA documents preserved as individual PDFs and organized by regulatory submission.

What's included

• Original FDA approval records
• 16 supplemental submissions represented
• 12 FDA review documents
• 17 approval letters
• 14 labeling documents
• FOIAdocs document index and detailed manifest

Package format: Organized ZIP collection with individual FDA PDFs grouped by regulatory submission, plus a FOIAdocs document index and manifest.

Application: NDA 206321
Product: Saxenda (liraglutide)
Sponsor: Novo Nordisk
Documents: 43
Pages: 1,999
Coverage: Original approval + 16 supplemental submissions represented